Replies to post #26659 on Amarin Corp Plc (AMRN)

[sts66]

What risks are Kowa taking? Seems to me not many - copromotion doesn't mean they have to higher more sales reps, they're already out there selling Livalo, which is going generic, as is their other product, Lipofen, a fenofibrate - the patent for Lipofen is due to expire on January 10, 2015. Seems to me both companies need each other to survive! Makes for a perfect pairing.

[BioChica]

It's funny remember the Amarin CEO was asked during the CC-Q&A, about a doing co-promo like this, he said no, it would be premature not having the Anchor approval (STATIN+VASCEPA). Now this makes me wonder, if powers to be know something about the future of Anchor approval. Makes me wonder!!